THE PROBIOTIC SUPER FORMULA

At time of manufacture, each capsule contains approximately 4.4 Billion organisms.

Jarro-Dophilus EPS™ is room temperature stable and enteric coated, delivering directly into the intestines 8 different species of probiotics representing 4 genera of bacteria:

Lactobacillus, Bifidobacteria,
Lactococcus and Pediococcus

• Bifidobacteria longum BB536 (morinaga strain) has been shown to colonize , stimulate immune response and suppress intestinal pathogens.
• L.rhamnosus R0011 is a unique, high producer of polysaccharides, which facilitate colonization and stimulate intestinal immune response.
• Lactococcus and Pediococcus help reduce spoilage caused by undesirable bacteria in cultured dairy products.

Storage: Refrigeration is not necessary. However, refrigeration is recommended in order to maintain the maximal survival and prolong the shelf life of the organisms

Other Ingredients: Potato Starch, magnesium stearate and ascorbic acid.

Vegetarian capsule consists of cellulose.
Suitable for Vegans.

Water-based enteric coating consists of hydroxypropyl methycllulose, magnesium silicate, methacrylate copolymer.

Contains NO common allergen.

A Broad Spectrum of Selected Strains

The intestines range from a relatively alkaline environment (pH) of the small intestine to an increasingly acidic environment in the large intestine. No one strain of bacteria can provide benefits throughout the entire length of the alimentary canal. This is the reason that Jarro-Dophilus EPS supplies eight different strains.

In the small intestine (duodenum, jejunum and ileum), the primary lactic flora that can be supplemented are the lactobacilli, although enterococci are also present. The large intestine exhibits a large proportion of bifidobacteria in addition to its components of lactobacilli and enterococci. The typical intestinal and vaginal flora include several species of lactic acid bacteria that perform different activities according to the nature of their enzyme systems. In the case of carbohydrate processing, for example, Lactobacillus rhamnosus ferments at least 24 different carbohydrates; L. acidophilus, 16; and L. delbrueckii subsp. bulgaricus, 7 different carbohydrates. This means that the lactic bacteria are important for completing the processing of carbohydrates in the gut. Bifidobacteria, which are located mainly in the large intestine, can ferment a variety of undigested carbohydrates, such as lactulose and oligosaccharides, and produce lactic and acetic acids, which are effective against pathogens and putrefactive bacteria (such as clostridia). The body’s own “friendly” bacteria are its best protection against pathogenic bacterial species and yeasts. 

Probiotic bacteria are important aids to normal digestion and assimilation beyond the simple processing of carbohydrates. Some species of lactic acid bacteria contribute to the digestion of proteins, some deconjugate bile salts and lower cholesterol levels, some produce specific antibiotics, while others stimulate the immune system. The eight different species found in Jarro-Dophilus EPS are representatives of four different genera: lactobacillus, bifidobacteria, lactococcus, and pediococcus. 

By supplying a mixture of species from among the most important lactobacilli isolated from the intestinal tract, including Lactobacillus rhamnosus, L. casei, L. plantarum, L. acidophilus and related species, Jarro-Dophilus EPS helps to safeguard all of these areas in which probiotics are so important for preserving health. Bifidobacterium longum BB536 (morinaga strain) has been shown in well-documented trials to stimulate immune response and to suppress intestinal pathogens. Lactobacillus rhamnosus R0011is a species that produces unique polysaccharides that not only augment intestinal immune response, but also facilitate probiotic colonization. Pediococcus helps to prevent pathogen-induced putrification in the gut and produces novel pediocins.

Requirements For Multi-Species Probiotic Success

There are several properties that are required from strains of lactic acid bacteria if these are to yield an efficient probiotic. No single strain can easily fulfill all these requirements. Therefore, a mixture of species is usually more suitable for supplementation. Among the most desirable properties of a good probiotic are the following:

•Compatibility among the strains.

•Ability to survive passage through the digestive tract.

•Stable under normal gastric conditions.

•Resistant to bile salts.

•Adherence to intestinal mucosa.

•colonization of the human intestinal tract.

•Safety with regard to human use.

•Production of anti-microbial substances.

•Antagonism against pathogenic and putrefactive bacteria.

•Human origin for human probiotics.

•Stability during storage under normal conditions.

4.36 Billions Organisms Per Capsule

At the time of manufacture, Jarro-Dophilus EPS supplies 4.36 billion live organisms per capsule. Even very hardy species of probiotics must be supplied in sufficient quantities if they are to properly colonize the gut and favorably influence bowel health. Advanced processing techniques now allow the production of very concentrated sources of probiotic bacteria that have been carefully selected for their harmonious interaction with one another.

Enteric Coated to Protect Against Stomach Acid

The ability to enteric coat live bacteria is yet another significant advance in the supplementation of probiotic strains for health. The acid of the stomach forms an important natural barrier against the entry of bacteria and yeasts into the rest of the digestive tract. However, this same barrier can impede probiotic supplementation. Now Jarro-Dophilus EPS bypasses the acid barrier and thereby gives superior results with fewer capsules.

Individually Blister-Sealed Capsules / Stable at Room Temperature

Each enteric-coated capsule is protected by its own blister-sealed chamber. This means that extraneous sources of moisture and oxygen are excluded. Moreover, the combination of superior starting materials, enteric-coating and individually sealed chambers means that Jarro-Dophilus EPS is stable at normal room temperature. Refrigeration is still recommended for better long-term storage, but at last it has become possible to take probiotics to areas without refrigeration without suffering a major loss in potency. The product is stable up to 2 years as long as the packaging is protected from excessive sources of heat, light, and other stresses. No other multi-species probiotic product can claim better stability.

Dairy Free–Hypoallergenic–Vegetarian

For those who are sensitive to dairy and other common allergens, Jarro-Dophilus EPS comes as a hypoallergenic dairy-free formulation supplied in vegetarian capsules manufactured from cellulose.

References

i. Alexander JG. (1971): “Lactobacillus casei tablets in the treament of intestinal infection.” J Royal Coll Gen Practitioners. 21: 623-624.

ii. Apella MC, Gonzalez SN, Nader de Macias ME, Romero N, Oliver G. (1992): “In vitro” studies on the inhibition of the growth of Shigella sonnei by actobacillus casei and L. acidophilus.” J. of Applied Bacteriology. 73 (6).

iii. Asano M, Karasawa E, Takayama T. (1986): “Antitumor activity of Lactobacillus casei (L.C. 9018) against experimental mouse bladder tumor (MBT-21).” J. Urol. 136 (3).

iv. Attebery HR, Sutter VL, Finegold SM. (1974): “Normal human intestinal flora. In anaerobic Bacteria - Role in Diseases:” Balows, A., De Haan, R.M., Dowell, V.R. and Guze, L.B. (eds) Springfield, Charles C. Thomas, Publ.

v. Choi S, et al. (1984): “Inhibition of pathogenic enterobacteria by Lactobacillus casei isolated from Yakult.” Korean J. of Veterinary Public Health, 8 (1).

vi. Clements ML, Levine MM, Ristaino PA, Daya VE, Hughes TP. (1983): “Exogenous lactobacilli fed to man - their fate and ability to prevent diarheal disease”. Prog, Food Nutr. Sci. 7 (3-4):29-37.

vii. Colombel JF, Cortot A, Neut C, Romond C. (1987). “Yoghourt with Bifidobacterium longum reduces erythromycin induced gastrointestinal effects.” Lancet 2: 43.

viii. De Vuyst L., Editor (1993): “Bacteriocins of Lactic Acid Bacteria.” Microbiology, Genetics and Applications, Blackie Academic and Professional, Chapman and Hall, London, 552 pages. Hoover DG; L.R. Steenson, Editors (1993): Bacteriocins of Lactic Acid Bacteria, Academic Press, Inc., New York, U.S.A., 275 pages.

ix. McGroarty JA, Reid G. (1988): “Detection of a Lactobacillus ( L. rhamnosus) substance that inhibits Escherichia coli.” Canadian J. of Microbiology, 34 (8).

x. Osmanagaoglu O, Beyatli Y, Gunduz U, Sacilik SC,  (2000):  “Analysis of the genetic determinant for production of the pediocin P of Pediococcus pentosaceus Pep1.”  J Basic Microbiol. 40(4): 233-41.

xi. Rasic JL, Kurmann JA. (1983) “Bifidobacteria and their role.” Experientia Supplementum, Birkhauser Verlag, Basel 39: 1-295.

xii. Reid G, et al. (1990): “Is there a role for lactobacilli in prevention of urogenital and intestinal infections?”  Clinical Microbiology Reviews. 3(4).